- Highlights
- Salk researchers investigated the impacts of entinostat, a drug that targets HDAC proteins, and found it inactivates DNA damage repair genes in pancreatic cancer cells
- The discovery led to new treatment strategies that pair entinostat with DNA-damaging therapies and the development of a nanoparticle-based delivery approach that limits toxicity by selectively delivering entinostat to tumors
- The findings could improve treatment outcomes and expand therapeutic options for pancreatic cancer, and similar strategies could be applied for treating other cancer types that resist DNA-damaging therapies
LA JOLLA—Pancreatic cancer is one of the deadliest cancers and is the third leading cause of cancer-related death in the United States. While scientists continue searching for new therapies, important advances can also come from understanding how existing drugs work. By uncovering the underlying biology, researchers can identify new ways to use existing drugs, improve their effectiveness, and overcome barriers…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
